ALCAR.PA stock is trading near €0.10 intraday on 16 Feb 2026 as investors brace for an earnings update on 18 Feb 2026. Volume is elevated at 807,348 shares versus a 30‑day average of 797,166, signalling higher interest ahead of results. Key metrics show EPS -1.15 and PE -0.09, underscoring current losses. We examine what the earnings release could mean for short‑term liquidity, surgical clinical milestones, and the share path on EURONEXT in Europe.
ALCAR.PA stock: earnings calendar and expectations
Carmat (ALCAR.PA) will report around clinical and operational updates on 18 Feb 2026. Investors expect commentary on implant cadence, regulatory steps, and cost control. One clear input is cash per share at 0.21 EUR, which frames runway questions. Analysts will watch guidance for 2026 and any change to trial timelines as immediate drivers of intraday moves.
Recent performance and valuation
Shares trade at €0.10 with a 52‑week range between €0.09 and €1.51. The 50‑day average is €0.15 and the 200‑day average is €0.59, showing steep year‑to‑date weakness. Market cap stands at €6,361,146.00 and enterprise value at €59,458,146.00, which reflect significant net debt and low liquidity. The negative PE of -0.09 and EPS -1.15 show the company remains loss‑making, so valuation depends on clinical progress rather than current earnings.
ALCAR.PA financials and operational metrics
Carmat reports revenue per share 0.31 EUR and free cash flow per share -1.97 EUR. The current ratio is 1.70, with cash per share 0.21 EUR. Inventory days are long at 1033 days, and the company shows negative operating cash flow per share of -1.90 EUR. These figures indicate capital intensity and working capital pressure. Expect management commentary on cash burn and financing plans in the earnings report.
Meyka AI rating and technical view
Meyka AI rates ALCAR.PA with a score out of 100: 72.71 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technical indicators show short‑term weakness: price sits below the 50‑day and 200‑day averages. Traders should note the average daily volume 807,348 suggests liquidity for intraday moves but wider spreads remain likely.
Catalysts, risks and sector context
Main catalysts are the 18 Feb 2026 earnings release, trial milestones, and any financing announcements. Key risks include continued cash burn, slow implant uptake, and regulatory setbacks. In the wider Healthcare Medical‑Devices sector, peers show stronger margins and higher ROE, so Carmat’s recovery depends on clinical proof points and capital raises. Short-term volatility is likely around the report.
News sources and market signals
For live quote and chart context see Reuters and comparative listings on Investing.com. Reuters coverage of ALCAR.PA and Investing.com comparisons including ALCAR.PA. Meyka AI provides real‑time model inputs on our platform for intraday traders and longer term investors.
Final Thoughts
Short term, ALCAR.PA stock trades at €0.099 with heightened volume ahead of the 18 Feb 2026 earnings announcement. The company remains loss‑making with EPS -1.15 and a negative PE, and working capital pressure is obvious from long inventory days and negative free cash flow per share. Meyka AI’s forecast model projects a 12‑month base scenario target of €0.18, implying an ~82.00% upside versus the current €0.099 price, while a downside stress case sits near €0.06 (about -39.39%). Forecasts are model‑based projections and not guarantees. Traders should weigh clinical updates and any near‑term financing news when sizing positions on EURONEXT in Europe. For live updates use Meyka AI’s AI‑powered market analysis platform and the Reuters feed linked above.
FAQs
When will Carmat report earnings and why does it matter?
Carmat’s earnings update is scheduled for 18 Feb 2026. The report matters because it will likely include implant data, cash burn figures, and guidance that can move the stock intraday on EURONEXT.
What is the current price and short‑term outlook for ALCAR.PA stock?
ALCAR.PA stock is trading at €0.099 intraday on 16 Feb 2026. Short‑term outlook depends on the earnings update; the stock is volatile and sensitive to clinical and financing news.
What are the main risks investors should watch?
Key risks include continued negative EPS, high inventory days, cash burn requiring financing, and potential trial or regulatory setbacks, all of which can widen intraday moves.
How does Meyka AI rate ALCAR.PA and what does it mean?
Meyka AI rates ALCAR.PA 72.71 out of 100 (B+) — BUY. The grade factors in benchmark and sector comparisons, growth, metrics, and analyst signals. Grades are informational and not investment advice.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)